Brokerages Set Structure Therapeutics Inc. (NASDAQ:GPCR) PT at $81.29

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) have earned an average recommendation of "Buy" from the eight ratings firms that are currently covering the firm, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have covered the stock in the last year is $81.29.

A number of analysts recently weighed in on the company. HC Wainwright restated a "buy" rating and issued a $80.00 target price on shares of Structure Therapeutics in a research report on Thursday, December 19th. Stifel Nicolaus began coverage on shares of Structure Therapeutics in a report on Wednesday, January 8th. They issued a "buy" rating and a $50.00 price objective for the company. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $91.00 target price on shares of Structure Therapeutics in a report on Wednesday, December 18th.

Structure Therapeutics Price Performance

GPCR stock traded down $0.68 during mid-day trading on Monday, hitting $30.02. 969,565 shares of the stock were exchanged, compared to its average volume of 793,619. The stock has a market capitalization of $1.72 billion, a price-to-earnings ratio of -40.57 and a beta of -2.76. The business has a fifty day moving average price of $29.40 and a 200 day moving average price of $35.03. Structure Therapeutics has a 12 month low of $23.50 and a 12 month high of $62.74.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Point72 Asset Management L.P. lifted its position in shares of Structure Therapeutics by 196.5% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,238,268 shares of the company's stock worth $54,348,000 after purchasing an additional 820,589 shares during the period. Janus Henderson Group PLC raised its position in shares of Structure Therapeutics by 18.0% in the 3rd quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company's stock worth $173,623,000 after purchasing an additional 602,609 shares during the last quarter. Vestal Point Capital LP raised its position in shares of Structure Therapeutics by 105.4% in the 3rd quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company's stock worth $50,474,000 after purchasing an additional 590,000 shares during the last quarter. FMR LLC boosted its stake in Structure Therapeutics by 6.7% in the 3rd quarter. FMR LLC now owns 6,128,444 shares of the company's stock worth $268,977,000 after purchasing an additional 383,635 shares in the last quarter. Finally, Principal Financial Group Inc. grew its position in Structure Therapeutics by 230.0% during the 3rd quarter. Principal Financial Group Inc. now owns 545,359 shares of the company's stock valued at $23,936,000 after purchasing an additional 380,115 shares during the last quarter. Institutional investors own 91.78% of the company's stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.